WT1 and acute myeloid leukemia: aAVC therapy is a cellular therapy platform, and we demonstrated that many types of antigens were used, such as OVA, MART-1, NY-ESO-1, and WT1 antigens in murine models (27–29, 34–36) and also against human relapsed and refractory acute myelogenous leukemia patients (37).